Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TT-816 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TT-816 | TT816|TT 816 | TT-816 is an antagonist of the cannabinoid receptor CB2R, which potentially leads to enhanced antitumor immune response and inhibition of tumor cell proliferation (Journal for ImmunoTherapy of Cancer 2022;10). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05525455 | Phase Ib/II | TT-816 TT-816 + unspecified PD-1 antibody | A Study in Patients With Advanced Cancers | Terminated | USA | 0 |